The FDA pushed back its decision date on Cytokinetics heart drug, while AstraZeneca got Phase 3 trial results that could help ...

The rare disease-focused biotech company posted adjusted earnings per share of $0.03, surpassing the analyst consensus estimate of -$0.02. However, revenue of $125.25 million missed Wall Street’s ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 ...

In one of the largest licensing deals in the Australian biotech industry, Dimerix Limited (ASX: DXB) has sealed an exclusive ...

Dimerix (ASX: DXB), an Australian drug developer, has entered into an exclusive US licensing agreement with Amicus ...

DMX-200 is a small molecule inhibitor of the chemokine receptor 2 (CCR2). The ACTION3 trial is a randomised, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients ...

Dimerix Ltd. sealed an exclusive license agreement with Amicus Therapeutics Inc. for commercialization of its phase III kidney disease candidate, DMX-200, in a deal valued at AU$940 million (US$601.22 ...

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) ...

Kidney drug developer Dimerix has struck a partnering deal with a Nasdaq listed company that could deliver more than $1 billion in payments.

Analysts are estimating that Amicus Therapeutics will report an earnings per share (EPS) of $0.08. The announcement from Amicus Therapeutics is eagerly anticipated, with investors seeking news of ...

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Amicus Therapeutics, Inc.